IL282479A - Type I interferon signatures and methods of use - Google Patents

Type I interferon signatures and methods of use

Info

Publication number
IL282479A
IL282479A IL282479A IL28247921A IL282479A IL 282479 A IL282479 A IL 282479A IL 282479 A IL282479 A IL 282479A IL 28247921 A IL28247921 A IL 28247921A IL 282479 A IL282479 A IL 282479A
Authority
IL
Israel
Prior art keywords
methods
type
interferon signatures
signatures
interferon
Prior art date
Application number
IL282479A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL282479A publication Critical patent/IL282479A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
IL282479A 2018-10-26 2021-04-20 Type I interferon signatures and methods of use IL282479A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751019P 2018-10-26 2018-10-26
PCT/IB2019/059178 WO2020084591A1 (en) 2018-10-26 2019-10-25 Type i interferon signatures and methods of use

Publications (1)

Publication Number Publication Date
IL282479A true IL282479A (en) 2021-06-30

Family

ID=70328348

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282479A IL282479A (en) 2018-10-26 2021-04-20 Type I interferon signatures and methods of use

Country Status (10)

Country Link
US (1) US12009079B2 (OSRAM)
EP (1) EP3873523A4 (OSRAM)
JP (2) JP2022512796A (OSRAM)
KR (1) KR20210084528A (OSRAM)
CN (1) CN113692287A (OSRAM)
CA (1) CA3117102A1 (OSRAM)
EA (1) EA202191133A1 (OSRAM)
IL (1) IL282479A (OSRAM)
MA (1) MA54085A (OSRAM)
WO (1) WO2020084591A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114836534A (zh) * 2021-06-08 2022-08-02 中国医学科学院北京协和医院 Samd9l基因突变作为i型干扰素病诊断的标志物及其应用
CA3266513A1 (en) 2022-09-14 2024-03-21 Viatris Asia Pacific Pte. Ltd. S1P1 RECEPTOR MODULATORS INTENDED FOR USE IN THE TREATMENT OF TYPE 1 IFN-MEDICATED DISEASES
WO2024100139A1 (en) * 2022-11-09 2024-05-16 Merck Patent Gmbh Use of ifn-i activity as a biomarker for tlr inhibitor treatment
WO2024173764A1 (en) * 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
EP4665349A1 (en) * 2023-02-16 2025-12-24 Alumis Inc. Methods of treating dermatological disorders
WO2024201091A1 (en) * 2023-03-27 2024-10-03 Institut National de la Santé et de la Recherche Médicale A gene signature for diagnosing stimulator of interferon genes (sting)-associated vasculopathy with onset in infancy (savi)
WO2024216160A1 (en) * 2023-04-14 2024-10-17 Arc Research Institute Methods and compositions for using peli2 as a biomarker
CN117138038A (zh) * 2023-09-21 2023-12-01 北京大学 一种预防、治疗或缓解椎体后纵韧带骨化症的药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613387A2 (pt) * 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
RU2527068C2 (ru) 2006-12-06 2014-08-27 Медиммун, Ллк Фармакодинамические маркеры, индуцированные интерфероном альфа
EP2068924A4 (en) * 2007-05-03 2011-07-20 Medimmune Llc INTERFERON ALPHA INDUCED PHARMACODYNAMIC MARKERS
EP2419727A1 (en) * 2009-04-14 2012-02-22 Schering Corporation Interferon-alfa sensitivity biomarkers
US20130261018A1 (en) * 2010-10-20 2013-10-03 University Of Tennessee Research Foundation Interferon gene signature and methods of use thereof
CA2834203A1 (en) * 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
RU2013157177A (ru) * 2011-05-25 2015-06-27 МЕДИММЬЮН, ЭлЭлСи Способы лечения системной красной волчанки, склеродермии и миозита
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102320059B1 (ko) * 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
US10689441B2 (en) * 2013-12-06 2020-06-23 Novimmune Sa Anti—TLR4 antibodies and methods of use thereof
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10689703B2 (en) * 2015-04-27 2020-06-23 National Jewish Health Methods of identifying and treating subjects having acute respiratory distress syndrome
CN109963870B (zh) * 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3947448A4 (en) * 2019-04-04 2023-02-01 Janssen Biotech, Inc. PROCEDURE FOR ADMINISTRATION OF AN ANTI-IFN ALPHA/OMEGA ANTIBODY

Also Published As

Publication number Publication date
JP2024119889A (ja) 2024-09-03
CA3117102A1 (en) 2020-04-30
CN113692287A (zh) 2021-11-23
EP3873523A1 (en) 2021-09-08
US20200131241A1 (en) 2020-04-30
EA202191133A1 (ru) 2021-07-12
KR20210084528A (ko) 2021-07-07
JP2022512796A (ja) 2022-02-07
WO2020084591A1 (en) 2020-04-30
US12009079B2 (en) 2024-06-11
MA54085A (fr) 2021-09-15
EP3873523A4 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
IL282479A (en) Type I interferon signatures and methods of use
SG11202104017VA (en) Tyk2 inhibitors and uses thereof
IL279458A (en) Neoantigens and their uses
IL283409A (en) tyk2 inhibitors and uses thereof
IL282090B1 (en) Tyk2 inhibitors and their uses
IL294052B1 (en) Fluoroalkyl oxadiazoles and their uses
ZA201808352B (en) Pegylated porcine interferon and methods of use thereof
IL281438A (en) Pyridazinones and methods of using them
IL283782A (en) Analosomes and methods of use
SG11202104010PA (en) Rgmc-selective inhibitors and use thereof
ZA202005674B (en) Glucoamylases and methods of use thereof
IL276053B1 (en) Therapeutic Gard and methods of its use
IL287503B2 (en) Thio-semicarbazide compounds and their use
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
GB201820842D0 (en) Sercurity documents and methods of manufacture thereof
IL276792A (en) Inhaler and methods for using it
IL281763A (en) documents and their production methods
IL280369A (en) Myokines and their uses
HK40059631A (en) Type i interferon signatures and methods of use
GB201808500D0 (en) Virus and virus use
HK40055592A (en) Catabodies and methods of use thereof
HK40043593A (en) Imidazodiazepinediones and methods of use thereof
HK40043133A (en) Inhaler and methods of use thereof
GB201812776D0 (en) New methods and uses
GB201716752D0 (en) Book arrangement and method of use thereof